在急性淋巴细胞白血病治疗期间对3岁患者使用简短神经认知测试组的可行性
Feasibility of Utilizing a Brief Neurocognitive Battery in 3-Year-Old Patients During Treatment for Acute Lymphoblastic Leukemia.
作者信息
Ramjan Sameera, Cole Peter D, Blair-Thies Melanie, Silverman Lewis B, Fredrickson Amy, Schembri Adrian, Welch Jennifer J Greene, Kahn Justine, Kelly Kara M, Tran Thai-Hoa, Michon Bruno, Gennarini Lisa, Sands Stephen A
机构信息
Department of Psychiatry & Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Rutgers Cancer Institute, New Brunswick, New Jersey, USA.
出版信息
Pediatr Blood Cancer. 2025 Mar;72(3):e31469. doi: 10.1002/pbc.31469. Epub 2024 Dec 9.
Treatment of acute lymphoblastic leukemia (ALL) is associated with neurocognitive deficits in young children. While computerized measures have been utilized in pediatric oncology research, they exclude patients below the age of 4 years. Patients enrolled on "Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents" were offered participation in an optional neurocognitive study. Three-year old patients did not differ from 4-year-old patients in their ability to perform or complete the tests. Including patients diagnosed at age 3 will serve to improve our understanding of at-risk patients and their neurocognitive trajectory both during and after treatment.
急性淋巴细胞白血病（ALL）的治疗与幼儿的神经认知缺陷有关。虽然计算机化测量已用于儿科肿瘤学研究，但这些测量方法将4岁以下的患者排除在外。参与“儿童和青少年新诊断急性淋巴细胞白血病的治疗”的患者可选择参加一项神经认知研究。3岁患者在执行或完成测试的能力方面与4岁患者没有差异。纳入3岁时被诊断出的患者将有助于提高我们对高危患者及其在治疗期间和治疗后的神经认知轨迹的理解。
Zotero 插件